417722-21-5

Basic information

• Product Name: 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE
• Synonyms: 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE;5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-Pyridinamine
• CAS NO: 417722-21-5
• Molecular Formula: C₁₆H₁₅N₃O₃
• Molecular Weight: 297.3086
• Mol File: 417722-21-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE(417722-21-5)
• EPA Substance Registry System: 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE(417722-21-5)

Safety Data

• Hazardous Substances Data: 417722-21-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE is used as a research compound for its potential therapeutic applications in various medical conditions. Its unique molecular structure positions it as a promising candidate for the development of new drugs.
Used in Cancer Treatment Research:
In the field of oncology, 5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE is studied for its potential as an anticancer agent, targeting various types of cancer through its interaction with cellular mechanisms.
Used in Inflammation Management:
5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE is also being investigated for its role in managing inflammation, given its capacity to modulate immune responses and potentially alleviate inflammatory conditions.
Used in Neurological Disorders Research:
5-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PYRIDIN-2-AMINE is explored for its potential to address neurological disorders, capitalizing on its ability to cross the blood-brain barrier and interact with specific neurological pathways.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, this compound serves as a key intermediate in the synthesis of more complex molecules with enhanced therapeutic effects, contributing to the advancement of novel drug entities.

Upstream product

• 666731-22-2 4-[(6-chloro-3-pyridinyl)oxy]-6,7-dimethoxy quinoline 
• 55717-45-8 6-bromo-pyridin-3-ol 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 1355031-22-9 4-((6-bromopyridin-3-yl)oxy)-6,7-dimethoxyquinoline 
• 41288-96-4 6-chloropyridine-3-ol 
• 109-00-2 3-HYDROXYPYRIDINE 
• 55717-46-9 6-aminopyridin-3-ol 
• 52092-47-4 5-chloro-2-nitropyridine 
• 6315-89-5 3,4-dimethoxyaniline 
• 26717-39-5 [[(3,4-Dimethoxyphenyl)amino]methylene]malonic acid,diethyl ester 
• 13436-14-1 ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate 
• 856965-37-2 2-amino-5-hydroxypyridine hydrochloride 
• 779345-37-8 5-fluoro-2-nitro-pyridine 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 

Downstream Products

• 1361235-64-4 N-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 

Relevant articles and documents

Structure activity relationships of quinoline-containing c-Met inhibitors

A series of quinoline-containing c-Met inhibitors were prepared and studied. Chemistry was developed to introduce a pyridyl moiety onto the 2-aryl ring present in a lead molecule which mitigated the potential for quinone formation relative to the original

Novel pyridine bioisostere of cabozantinib as a potent c-met kinase inhibitor: Synthesis and anti-tumor activity against hepatocellular carcinoma

Two novel bioisosteres of cabozantinib, 3 and 4, were designed and synthesized. The ben-zene ring in the center of the cabozantinib structure was replaced by trimethylpyridine (3) and pyridine (4), respectively. Surprisingly, the two compounds showed extremely contrasting mesenchy-mal–epithelial transition factor (c-Met) inhibitory activities at 1 μM concentration (4% inhibition of 3 vs. 94% inhibition of 4). The IC50 value of compound 4 was 4.9 nM, similar to that of cabozantinib (5.4 nM). A ligand-based docking study suggested that 4 includes the preferred conformation for the binding to c-Met in the conformational ensemble, but 3 does not. The anti-proliferative activity of compound 4 against hepatocellular carcinoma (Hep3B and Huh7) and non-small-cell lung cancer (A549 and H1299) cell lines was better than that of cabozantinib, whereas 3 did not show a signifi-cant anti-proliferative activity. Moreover, the tumor selectivity of compound 4 toward hepatocellu-lar carcinoma cell lines was higher than that of cabozantinib. In the xenograft chick tumor model, compound 4 inhibited Hep3B tumor growth to a much greater extent than cabozantinib. The present study suggests that compound 4 may be a good therapeutic candidate against hepatocellular carci-noma.

Novel quinoline derivative inhibitor

The invention provides a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). According to the invention, the compound provided by the invention can selectively inhibit tyrosine kinase TAM family/an

ETHANE-SULFONATE SALT OF QUINOLINE DERIVATIVE

The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.

TAM family kinase and/or CSF1R kinase inhibitor and application thereof

The invention provides a novel inhibitor compound shown in a general formula (I). The compound has good kinase inhibition activity and can be used for preventing and/or treating diseases mediated by abnormal expression of TAM family kinase and/or a ligand thereof. The compound can target CSF1R kinase and can be used for preventing and/or treating diseases mediated by abnormal expression of a TAM family kinase receptor and/or a CSF1R kinase receptor and/or ligands thereof.

Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors

While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to establish

QUINOLINE DERIVATIVE

This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases.

Quinoline derivatives (by machine translation)

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.

NITROGENATED AROMATIC HETEROCYCLIC RING DERIVATIVE

The present invention provides a nitrogen-containing aromatic heterocyclic derivative represented by formula (I): [wherein W represents CR3 (wherein R3 represents a hydrogen atom or the like) or the like, R4 represents a hydrogen atom or the like, R5 represents a hydrogen atom or the like, R9 represents substituted imidazolyl, R12 and R13 may be the same or different, each represent a hydrogen atom or the like, R22 and R23 may be the same or different, each represent a hydrogen atom or the like, R24 represents a hydrogen atom or the like, Y represents C-R25 (wherein R25 represents a hydrogen atom or the like) or the like] or a pharmaceutically acceptable salt thereof and a FGFR inhibitor comprising, as an active ingredient, the nitrogen-containing aromatic heterocyclic derivative or the pharmaceutically acceptable salt thereof, or the like.

Pharmaceutically active compounds as Axl inhibitors

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.